Inclusion Criteria:

          1. Individuals with histologically documented metastatic or locally advanced unresectable
             UC defined as

               -  Tumor (T) 4b, any node (N) or

               -  Any T, N 2-3 Tumors of upper and lower urinary tract are permitted. Mixed
                  histologic types are allowed if urothelial is the predominant histology.

          2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.

          3. Individuals with progression or recurrence following receipt of platinum-containing
             regimen and anti programmed cell death protein 1/programmed death-ligand 1
             (PD-1/PD-L1) therapy for metastatic or locally advanced unresectable disease will be
             enrolled.

               -  a. Individuals with recurrence or progression ≤12 months following completion of
                  cisplatin-containing chemotherapy given in the neo-adjuvant/adjuvant setting may
                  utilize that line of therapy to be eligible for the study. The 12-month period is
                  counted from completion of surgical intervention or platinum therapy,
                  respectively. These individuals must receive anti PD-1/PD-L1 therapy in the
                  metastatic or locally advanced unresectable setting to be eligible.

               -  b. Individuals who received either carboplatin or anti PD-1/PD-L1 therapy in the
                  neo- adjuvant/adjuvant setting will not be able to count that line of therapy
                  towards eligibility for the study.

               -  c. Cisplatin ineligible individuals who meet one of the below criteria and who
                  were treated with carboplatin in the metastatic or locally advanced unresectable
                  settings may count that line of therapy towards eligibility. They must then have
                  received anti PD-1/PD-L1 therapy in metastatic or locally advanced unresectable
                  setting to be eligible for the study.

                    -  Cisplatin ineligibility is defined as meeting one of the following criteria:

                         -  1. Creatinine Clearance < 60 mL/min

                         -  2. Grade ≥ 2 Audiometric Hearing Loss

                         -  3. Grade ≥ 2 Peripheral Neuropathy

                         -  4. New York Heart Association (NYHA) Class III heart failure

                         -  5. ECOG PS ≥ 2

               -  d. Anti PD-1/PD-L1 therapy administered as part of maintenance therapy may be
                  counted towards eligibility for the study

               -  e. Individuals who received only concurrent chemoradiation for bladder
                  preservation without further systemic therapy are not eligible to enroll in the
                  study. The substitution of carboplatin for cisplatin does not constitute a new
                  regimen provided no new chemotherapeutic agents were added to the regimen and no
                  progression was noted prior to the change in platinum.

          4. Individuals with previously treated brain metastases may participate in the study
             provided they have stable CNS disease for at least 4 weeks prior to the first dose of
             study drug and stabilization of all neurologic symptoms, have no evidence of new or
             enlarging brain metastases, and are not using steroids >20 mg of prednisone (or
             equivalent) daily for brain metastases for at least 7 days prior to first dose of the
             study drug.

          5. Adequate hematologic counts without transfusion or growth factor support within 1 week
             of study drug initiation (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC)
             ≥1,500/mm^3, and platelets ≥100,000/µL).

          6. Adequate hepatic function (bilirubin ≤1.5x institutional upper limit of normal (IULN),
             aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x IULN or

             ≤ 5 x IULN if known liver metastases and serum albumin >3 g/dL).

             Docetaxel will only be option in TPC arm for Individuals with a total bilirubin ≤1 x
             IULN, and an AST and/or ALT ≤1.5x IULN if alkaline phosphatase is also >2.5 x IULN.

          7. Creatinine clearance ≥30 mL/min as assessed by the Cockcroft-Gault equation or other
             validated instruments (e.g. Modification of Diet in Renal Disease (MDRD) equation).

          8. Females of childbearing potential must have a negative urine or serum pregnancy test
             within 72 hours prior to receiving the first dose of study drug. If the urine test is
             positive or cannot be confirmed as negative, a serum pregnancy test will be required.

          9. Females of childbearing potential must be willing to use 2 methods of birth control or
             be surgically sterile or abstain from heterosexual activity for the course of the
             study through 6 months after the last dose of study drug. Individuals of childbearing
             potential are those who have not been surgically sterilized or have not been free from
             menses for >2 years.

         10. Male individuals must agree to use an adequate method of contraception starting with
             the first dose of study therapy through 3 months after the last dose of study therapy.

        Exclusion Criteria:

          1. Females who are pregnant or lactating.

          2. Have had a prior anti-cancer monoclonal antibody (mAb)/ antibody-drug conjugate (ADC)
             within 4 weeks prior to Cycle 1 Day 1 (C1D1) or have had prior chemotherapy, targeted
             small molecule therapy, or radiation therapy within 2 weeks prior to C1D1. Individuals
             participating in observational studies are eligible.

          3. Have received prior chemotherapy for UC with all available SOC therapies in the
             control arm (i.e., both prior paclitaxel and docetaxel in regions where vinflunine is
             not an approved therapy, or prior paclitaxel, docetaxel and vinflunine in regions
             where vinflunine is an approved therapy).

          4. Have not recovered (i.e., ≤ Grade 1) from AEs due to previously administered
             chemotherapeutic agent.

               -  Note: Individuals with ≤ Grade 2 neuropathy or any grade of alopecia are an
                  exception to this criterion and will qualify for the study.

               -  Note: If Individuals received major surgery, they must have recovered adequately
                  from the toxicity and/or complications from the intervention prior to starting
                  study therapy.

          5. Have previously received topoisomerase 1 inhibitors.

          6. Have an active second malignancy.

             • Note: Individuals with a history of malignancy that have been completely treated and
             with no evidence of active cancer for 3 years prior to enrollment, or individuals with
             surgically cured tumors with low risk of recurrence are allowed to enroll in the study
             after discussion with the medical monitor.

          7. Have active cardiac disease, defined as:

               -  Myocardial infarction or unstable angina pectoris within 6 months of C1D1.

               -  History of serious ventricular arrhythmia (i.e., ventricular tachycardia or
                  ventricular fibrillation), high-grade atrioventricular block, or other cardiac
                  arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation
                  that is well controlled with antiarrhythmic medication); history of QT interval
                  prolongation.

               -  NYHA Class III or greater congestive heart failure or left ventricular ejection
                  fraction of <40%.

          8. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease)
             or gastrointestinal (GI) perforation within 6 months of enrollment.

          9. Have an active serious infection requiring anti-infective therapy (Contact medical
             monitor for clarification).

         10. Have known history of Human Immunodeficiency Virus (HIV)-1/2 with undetectable viral
             load and on medications that may interfere with SN-38 metabolism.

         11. Have active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). In individuals with a
             history of HBV or HCV, individuals with a detectable viral load will be excluded.

         12. Have other concurrent medical or psychiatric conditions that, in the investigator's
             opinion, may be likely to confound study interpretation or prevent completion of study
             procedures and follow-up examinations.

         13. Have inability to tolerate or are allergic to any potential TPC agent or sacituzumab
             govitecan-hziy or unable or unwilling to receive the doses specified in the protocol.

         14. Have inability to complete all specified study procedures for any reason.